Abstract:536 Background: Early-onset cholangiocarcinoma (eoCCA) is among early-onset cancers with the fastest rising rates, yet little is known about its biology. We sought to compare the molecular characteristics of eoCCA with average-onset CCA (aoCCA) with an age cut-off of 50 years, utilizing a real-world multi-omics dataset. Methods: The study comprised patients whose tumors underwent molecular analysis at Caris Life Sciences (Phoenix, AZ) using whole exome and whole transcriptome analyses. Patients were categorized by age as eoCCA defined as 50 years. Gene expression profiles were analyzed for transcriptional signatures predictive of immunotherapy response including the T-cell inflamed score (TIS) and interferon-gamma (IFG) score. P values (adjusted for multiple testing) were considered significant at False Discovery Rate (FDR) P<0.05 for molecular comparisons and FDR P<0.25 for Gene Set Enrichment Analysis (GSEA). Insurance claims data was used for survival comparison using Kaplan-Meier estimates. Results: The study included 5587 patients - 453 patients with eoCCA and 5134 with aoCCA (Table). Of targetable mutations ( FGFR2, IDH1, IDH2, ERBB2, BRCA, BRAF), FGFR2 fusion was significantly more prevalent in eoCCA (15.7% vs 5.9% in aoCCA, FDR P<0.001). Rates trended higher in eoCCAfor MSI-H tumors (4.1% vs 2.4%), and high tumor mutational burden (6.1% vs 5.1%) but not significantly different (FDR P=1). The IFG score (Fold Change FC: 1.1, FDR P=0.01) and TIS (FC:17.3, FDR P=0.03) were significantly higher in aoCCA vs eoCCA. On GSEA, angiogenesis was enriched in eoCCA (normalized enrichment score NES=1.51, FDR P=0.16) while IFG (NES= -1.58, FDR P =0.06) and inflammatory response (NES= -1.46, FDR P=0.18) were enriched in aoCCA. Median OS was longer in eoCCA (16.5 vs 13.3 months, Hazard Ratio (HR) 0.86, 95%CI 0.78-0.95, P=0.004). Among patients treated with immunotherapy, median OS was longer in patients with eoCCA (19.2 months, n=19) vs aoCCA (7.6 months, n=150) - HR 0.52, 95%CI 0.28-0.94, p=0.03. No survival difference was identified in patients on chemotherapy (HR 0.91, 95%CI 0.76-1.08, P=0.28). Conclusions: In the largest age-stratified analysis of molecular characteristics of CCA, we identified crucial differences, including higher prevalence of FGFR2 fusions and significant differences in immunotherapy-related markers, angiogenesis enrichment, and inflammatory response. Patients with eoCCA experienced better outcomes with immunotherapy even though immune-oncology-relevant markers favored aoCCA. Our findings, especially higher FGFR2 fusion prevalence in eoCCA, underscore the need for NGS testing and the potential for age-tailored therapeutic strategies. [Table: see text]

Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data

Clinical Characteristics, Treatment Patterns and Survival Outcomes of Early-Onset Pancreatic Adenocarcinoma: a Population-Based Study

Prognostic Analysis of Very Early Onset Pancreatic Cancer: a Population-Based Analysis.

Clinical and prognostic characteristics of early onset metastatic pancreatic cancer.

Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center

The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis

The Global Burden of Early-Onset Pancreatic Cancer and Its Risk Factors

Early Onset Pancreatic Adenocarcinoma (EOPAC): presentation, clinical course and treatment outcomes in comparison to Average Onset Pancreatic Adenocarcinoma (AOPAC): a retrospective cohort study

Germline testing in patients with early-onset pancreatic cancer (EOPC).

Abstract IA15: What the surgeon has learned from pancreas cancer genomics, and vice versa

The Real-World Study of the Clinical Characteristics, Diagnosis, and Treatment of Advanced Pancreatic Cancer in China

An Overview of Pancreatic Cancer Diagnosis and Treatment in China: Current Landscape and Future Prospects

Early-Onset colorectal Cancer: From the laboratory to the clinic

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Risk factors, histopathological landscape, biomarkers, treatment patterns and survival of early‐onset colorectal cancer: A narrative review

Early detection of pancreatic cancer: current state and future opportunities

Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

Pancreatic cancer treatment: better, but a long way to go

The Clinical Characteristics and Survival Associations of Pancreatic Neuroendocrine Tumors: Does Age Matter?

Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.